If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 315.50
Ask: 317.00
Change: -5.00 (-1.56%)
Spread: 1.50 (0.475%)
Open: 327.00
High: 329.50
Low: 315.00
Prev. Close: 320.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: BoA likes Dowlais; JPMorgan cuts Phoenix Group

Fri, 22nd Sep 2023 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

----------

FTSE 100

----------

UBS raises Next price target to 7,250 (6,850) pence - 'neutral'

----------

SocGen raises Next price target to 8,287 (8,239) pence - 'buy'

----------

JPMorgan raises Next price target to 7,500 (7,300) pence - 'neutral'

----------

JPMorgan raises Next price target to 7,500 (7,300) pence - 'neutral'

----------

Goldman Sachs cuts SSE price target to 2,390 (2,431) pence - 'buy'

----------

JPMorgan raises M&G price target to 195 (180) pence - 'underweight'

----------

JPMorgan raises Admiral Group price target to 1,700 (1,650) pence - 'underweight'

----------

JPMorgan cuts Phoenix Group to 'underweight' (neutral) - price target 500 (655) pence

----------

JPMorgan cuts Prudential price target to 1,500 (1,630) pence - 'overweight'

----------

JPMorgan cuts Legal & General price target to 290 (315) pence - 'overweight'

----------

RBC raises Hargreaves Lansdown target to 900 (875) pence - 'sector perform'

----------

Deutsche Bank cuts Lloyds Banking price target to 62 (63) pence - 'buy'

----------

Deutsche Bank cuts Barclays price target to 200 (230) pence - 'hold'

----------

Deutsche Bank cuts NatWest price target to 320 (370) pence - 'buy'

----------

JPMorgan raises BP price target to 600 (530) pence - 'neutral'

----------

JPMorgan raises Shell price target to 3,200 (2,750) pence - 'overweight'

----------

FTSE 250

----------

Bank of America starts Dowlais with 'buy' - price target 144 pence

----------

Jefferies cuts Victrex price target to 1,420 (1,590) pence - 'hold'

----------

JPMorgan raises Hiscox to 'overweight' (neutral) - price target 1,300 (1,200) pence

----------

JPMorgan raises Just Group price target to 125 (120) pence - 'overweight'

----------

JPMorgan cuts Lancashire to 'neutral' (overweight) - price target 715 (750) pence

----------

Berenberg cuts Mobico Group price target to 140 (220) pence - 'buy'

----------

Deutsche Bank cuts Dunelm price target to 1,310 (1,340) pence - 'buy'

----------

Deutsche Bank cuts Virgin Money UK target to 210 (220) pence - 'hold'

----------

SMALL CAP

----------

Berenberg raises DFS Furniture price target to 185 (155) pence - 'buy'

----------

JPMorgan cuts Oxford BioMedica price target to 325 (495) pence - 'neutral'

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.